Picard Medical Faces Shareholder Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy PMI?
Source: Globenewswire
- Lawsuit Background: Picard Medical, Inc. (NYSE American: PMI) is facing a shareholder class action lawsuit alleging that the company issued false and misleading statements while failing to disclose significant adverse facts related to stock price manipulation.
- Fraud Allegations: The lawsuit claims that Picard was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals, resulting in investor losses.
- Insider Trading: Additionally, the lawsuit accuses insiders or affiliates of using offshore or nominee accounts to facilitate coordinated share dumping during a price inflation campaign, further harming investor interests.
- Legal Consultation Information: Investors who purchased Picard shares between September 2, 2025, and October 31, 2025, and experienced significant losses are encouraged to contact Holzer & Holzer, LLC for legal rights information, with the deadline to apply as lead plaintiff set for April 3, 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PMI
About PMI
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Picard Medical Faces Shareholder Class Action Lawsuit
- Lawsuit Background: Picard Medical, Inc. (NYSE American: PMI) is facing a shareholder class action lawsuit alleging that the company issued false and misleading statements while failing to disclose significant adverse facts related to stock price manipulation.
- Fraud Allegations: The lawsuit claims that Picard was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals, resulting in investor losses.
- Insider Trading: Additionally, the lawsuit accuses insiders or affiliates of using offshore or nominee accounts to facilitate coordinated share dumping during a price inflation campaign, further harming investor interests.
- Legal Consultation Information: Investors who purchased Picard shares between September 2, 2025, and October 31, 2025, and experienced significant losses are encouraged to contact Holzer & Holzer, LLC for legal rights information, with the deadline to apply as lead plaintiff set for April 3, 2026.
See More
Picard Medical Partners with Hydrix to Develop Next-Gen Total Artificial Heart
- Collaboration Agreement: On January 5, 2026, Picard Medical entered into a development collaboration agreement with Hydrix to initiate the initial development phase for the next-generation fully implantable Total Artificial Heart, Emperor, aimed at enhancing patient mobility and convenience.
- Selection of Technical Expertise: SynCardia chose Hydrix as a partner based on its proven expertise in complex critical engineering and successful track record in developing regulated medical devices, reflecting Picard's commitment to high-value development programs.
- R&D Tax Incentives: This collaboration may allow Picard to benefit from approximately 43% Australian R&D tax incentives, further reducing development costs and accelerating technological advancements, thereby enhancing market competitiveness.
- Multi-Stage Development Plan: Under the agreement, Hydrix will perform development work for Picard and SynCardia through the end of 2026, with the program structured to advance through defined engineering verification and regulatory milestones, ensuring compliance with technical progress and safety validation.
See More
Picard Medical Partners with Hydrix to Develop Next-Gen Total Artificial Heart
- Collaboration Agreement: On January 5, 2026, Picard Medical entered into a development collaboration agreement with Hydrix to initiate the initial development phase for the next-generation fully implantable Total Artificial Heart, Emperor, aimed at enhancing patient mobility and convenience.
- Strategic Partner Selection: SynCardia chose Hydrix based on its proven expertise in complex critical engineering and a strong track record in developing regulated medical devices, reflecting Picard's commitment to high-value long-term development programs.
- Tax Incentive Potential: The collaboration may allow Picard to benefit from Australian R&D tax incentives of approximately 43% of eligible expenditure, providing additional financial support to foster technological advancements.
- Multi-Stage Development Plan: Under the agreement, Hydrix will conduct development work through the end of 2026, with the program structured to advance through defined engineering verification and regulatory milestones, ensuring compliance with safety validation and technical progress for long-term objectives.
See More
Picard Medical Attends J.P. Morgan Healthcare Conference to Showcase Artificial Heart Technology
- Industry Conference Participation: Picard Medical will attend the J.P. Morgan Healthcare Conference and related events on January 12 and 14, 2026, showcasing its innovations in cardiac care to enhance the company's visibility and influence in the healthcare sector.
- Technological Leadership: As the world's first manufacturer of a total artificial heart approved by both the FDA and Health Canada, Picard Medical's SynCardia system has performed over 2,100 implants across 27 countries, highlighting its market leadership in treating heart failure.
- Market Expansion Opportunities: By participating in LifeSci Advisors' Corporate Access Event, Picard Medical aims to engage in one-on-one meetings with potential investors and partners, further driving strategic collaborations and market expansion in the medtech field.
- Innovative Product Showcase: The SynCardia Total Artificial Heart is the only commercially available artificial heart in the U.S. and Canada, and this conference is expected to provide a crucial platform for future market promotion and product development.
See More
Picard Medical (PMI) Enhances SynCardia Heart Design with CPC Connector Covers for Improved Patient Safety
- Design Upgrade: Picard Medical announced the incorporation of FDA-cleared CPC1 connector covers into its SynCardia Total Artificial Heart design, aimed at enhancing patient safety and quality of life, which is expected to significantly reduce potential risks associated with metal release buttons.
- Clinical Implementation: The rollout of these covers is scheduled for January 15, 2026, in standard clinical practice in the U.S., not only improving patient experience but also increasing healthcare institutions' trust in the SynCardia system.
- Market Response: During pre-market trading, PMI's stock rose by 0.42% to $1.69, reflecting positive market expectations regarding the new design, which may attract more investor interest.
- Strategic Implications: This design improvement aligns with FDA safety standards and demonstrates Picard Medical's commitment to patient safety, which is expected to enhance its competitiveness in the artificial heart market and drive future sales growth.
See More
Picard Medical Secures $50 Million Private Placement to Support Artificial Heart Operations
- Financing Agreement: Picard Medical has entered into a definitive agreement with WestPark Capital to raise up to $50 million through a private placement of senior secured notes, aimed at expanding and supporting its artificial heart operations.
- Initial Financing Arrangement: The company expects to issue $15 million in notes at closing, with the option to fund an additional $35 million based on certain conditions, enhancing its financial flexibility.
- Clear Use of Proceeds: The net proceeds from this financing will be used for working capital and general corporate purposes, aimed at strengthening the company's competitive position in the heart disease treatment market.
- Market Leadership: Picard Medical's SynCardia system is the only total artificial heart approved by both the FDA and Health Canada, with over 2,100 implants performed across 27 countries, solidifying its leadership in the heart disease treatment market.
See More
Picard Medical Faces Shareholder Class Action Lawsuit
- Lawsuit Background: Picard Medical, Inc. (NYSE American: PMI) is facing a shareholder class action lawsuit alleging that the company issued false and misleading statements while failing to disclose significant adverse facts related to stock price manipulation.
- Fraud Allegations: The lawsuit claims that Picard was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals, resulting in investor losses.
- Insider Trading: Additionally, the lawsuit accuses insiders or affiliates of using offshore or nominee accounts to facilitate coordinated share dumping during a price inflation campaign, further harming investor interests.
- Legal Consultation Information: Investors who purchased Picard shares between September 2, 2025, and October 31, 2025, and experienced significant losses are encouraged to contact Holzer & Holzer, LLC for legal rights information, with the deadline to apply as lead plaintiff set for April 3, 2026.
See More
Picard Medical Partners with Hydrix to Develop Next-Gen Total Artificial Heart
- Collaboration Agreement: On January 5, 2026, Picard Medical entered into a development collaboration agreement with Hydrix to initiate the initial development phase for the next-generation fully implantable Total Artificial Heart, Emperor, aimed at enhancing patient mobility and convenience.
- Selection of Technical Expertise: SynCardia chose Hydrix as a partner based on its proven expertise in complex critical engineering and successful track record in developing regulated medical devices, reflecting Picard's commitment to high-value development programs.
- R&D Tax Incentives: This collaboration may allow Picard to benefit from approximately 43% Australian R&D tax incentives, further reducing development costs and accelerating technological advancements, thereby enhancing market competitiveness.
- Multi-Stage Development Plan: Under the agreement, Hydrix will perform development work for Picard and SynCardia through the end of 2026, with the program structured to advance through defined engineering verification and regulatory milestones, ensuring compliance with technical progress and safety validation.
See More
Picard Medical Partners with Hydrix to Develop Next-Gen Total Artificial Heart
- Collaboration Agreement: On January 5, 2026, Picard Medical entered into a development collaboration agreement with Hydrix to initiate the initial development phase for the next-generation fully implantable Total Artificial Heart, Emperor, aimed at enhancing patient mobility and convenience.
- Strategic Partner Selection: SynCardia chose Hydrix based on its proven expertise in complex critical engineering and a strong track record in developing regulated medical devices, reflecting Picard's commitment to high-value long-term development programs.
- Tax Incentive Potential: The collaboration may allow Picard to benefit from Australian R&D tax incentives of approximately 43% of eligible expenditure, providing additional financial support to foster technological advancements.
- Multi-Stage Development Plan: Under the agreement, Hydrix will conduct development work through the end of 2026, with the program structured to advance through defined engineering verification and regulatory milestones, ensuring compliance with safety validation and technical progress for long-term objectives.
See More
Picard Medical Attends J.P. Morgan Healthcare Conference to Showcase Artificial Heart Technology
- Industry Conference Participation: Picard Medical will attend the J.P. Morgan Healthcare Conference and related events on January 12 and 14, 2026, showcasing its innovations in cardiac care to enhance the company's visibility and influence in the healthcare sector.
- Technological Leadership: As the world's first manufacturer of a total artificial heart approved by both the FDA and Health Canada, Picard Medical's SynCardia system has performed over 2,100 implants across 27 countries, highlighting its market leadership in treating heart failure.
- Market Expansion Opportunities: By participating in LifeSci Advisors' Corporate Access Event, Picard Medical aims to engage in one-on-one meetings with potential investors and partners, further driving strategic collaborations and market expansion in the medtech field.
- Innovative Product Showcase: The SynCardia Total Artificial Heart is the only commercially available artificial heart in the U.S. and Canada, and this conference is expected to provide a crucial platform for future market promotion and product development.
See More
Picard Medical (PMI) Enhances SynCardia Heart Design with CPC Connector Covers for Improved Patient Safety
- Design Upgrade: Picard Medical announced the incorporation of FDA-cleared CPC1 connector covers into its SynCardia Total Artificial Heart design, aimed at enhancing patient safety and quality of life, which is expected to significantly reduce potential risks associated with metal release buttons.
- Clinical Implementation: The rollout of these covers is scheduled for January 15, 2026, in standard clinical practice in the U.S., not only improving patient experience but also increasing healthcare institutions' trust in the SynCardia system.
- Market Response: During pre-market trading, PMI's stock rose by 0.42% to $1.69, reflecting positive market expectations regarding the new design, which may attract more investor interest.
- Strategic Implications: This design improvement aligns with FDA safety standards and demonstrates Picard Medical's commitment to patient safety, which is expected to enhance its competitiveness in the artificial heart market and drive future sales growth.
See More
Picard Medical Secures $50 Million Private Placement to Support Artificial Heart Operations
- Financing Agreement: Picard Medical has entered into a definitive agreement with WestPark Capital to raise up to $50 million through a private placement of senior secured notes, aimed at expanding and supporting its artificial heart operations.
- Initial Financing Arrangement: The company expects to issue $15 million in notes at closing, with the option to fund an additional $35 million based on certain conditions, enhancing its financial flexibility.
- Clear Use of Proceeds: The net proceeds from this financing will be used for working capital and general corporate purposes, aimed at strengthening the company's competitive position in the heart disease treatment market.
- Market Leadership: Picard Medical's SynCardia system is the only total artificial heart approved by both the FDA and Health Canada, with over 2,100 implants performed across 27 countries, solidifying its leadership in the heart disease treatment market.
See More
